{
    "id": 27032,
    "fullName": "CD79B mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CD79B mutant indicates an unspecified mutation in the Cd79b gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 974,
        "geneSymbol": "CD79B",
        "terms": [
            "CD79B",
            "AGM6",
            "B29",
            "IGB"
        ]
    },
    "variant": "mutant",
    "createDate": "10/04/2017",
    "updateDate": "09/19/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12113,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of Sapanisertib (MLN0128) and Imbruvica (ibrutinib) resulted in a synergistic effect, inducing cell death in primary central nervous system lymphoma cells harboring a CD79B mutation in culture (PMID: 28619981).",
            "molecularProfile": {
                "id": 28417,
                "profileName": "CD79B mutant"
            },
            "therapy": {
                "id": 6296,
                "therapyName": "Ibrutinib + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 3234,
                "name": "central nervous system lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12112,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of Aliqopa (copanlisib) and Imbruvica (ibrutinib) resulted in a synergistic effect, inducing cell death and inhibiting the PI3K/mTOR pathway in primary central nervous system lymphoma cells harboring a CD79B mutation in culture (PMID: 28619981).",
            "molecularProfile": {
                "id": 28417,
                "profileName": "CD79B mutant"
            },
            "therapy": {
                "id": 6295,
                "therapyName": "Copanlisib + Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3234,
                "name": "central nervous system lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12254,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, all the diffuse large B-cell lymphoma patients harboring both MYD88 L265P and CD79B mutations (n=4) responded to Imbruvica (ibrutinib) treatment (Blood 2012, 120 (21): 686).",
            "molecularProfile": {
                "id": 28604,
                "profileName": "CD79B mut MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10215,
                    "pubMedId": null,
                    "title": "The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study",
                    "url": "http://www.bloodjournal.org/content/120/21/686?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28417,
            "profileName": "CD79B mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28604,
            "profileName": "CD79B mut MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}